Menu Back toSession-2-Advanced-Therapy-Medicinal-Products-ATMPs-Do-They-Hold-What-They-Promise

Better Medicines for Children, A DIA/EFGCP Conference

Plan ahead and join us to reflect on the importance of two major headways that are currently affecting Paediatric research: Innovative approaches to Drug Development and impact of the current environment on the Regulatory and Research Infrastructure


Session 2: Advanced Therapy Medicinal Products (ATMPs) – Do They Hold What They Promise?

Session Chair(s)

Katie  Rizvi

Katie Rizvi

  • Founder, Little People Association & Temerarii Club
  • The Romanian Community of Cancer Survivor Adolescents and Young Adults, Romania
Session 2: Advanced Therapy Medicinal Products (ATMPs) – Do They Hold What They Promise?

Speaker(s)

Anja  Schiel, PhD

Advances in ATMP Development - Regulator Perspective

Anja Schiel, PhD

  • Senior Adviser/Statistician, Unit for HTA and Reimbursement
  • Norwegian Medicines Agency (NoMA), Norway
Mette  Due Theilade Thomsen, PhD

Paediatric ATMP Development– Industry Initial Learnings

Mette Due Theilade Thomsen, PhD

  • Managing Director
  • PIP Adviser, Denmark
Elizabeth  Vroom

Paediatric ATMP Development– Patients’ Experience

Elizabeth Vroom

  • President
  • Duchenne Parent Project, Netherlands

Contact us


Registration Questions?

Send Email
+41 61 225 51 51